Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: - | CAS number: -
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Link to relevant study record(s)
- Endpoint:
- basic toxicokinetics in vivo
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Objective of study:
- metabolism
- toxicokinetics
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 417 (Toxicokinetics)
- Version / remarks:
- 1984
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.36 (Toxicokinetics)
- Version / remarks:
- 1988
- Deviations:
- no
- GLP compliance:
- yes (incl. QA statement)
- Radiolabelling:
- yes
- Species:
- rat
- Strain:
- other: CD / Crl:CD(SD)
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Ltd., Sulzfeld, Germany
- Age at study initiation: 7 weeks (males), 9-12 weeks (females)
- Weight at study initiation: 228–252 g (males), 210–288 g (females)
- Fasting period before study: no
- Housing: individually
- Individual metabolism cages: no
- Diet: ad libitum
- Water: ad libitum
- Acclimation period: 5-8 d
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22±3
- Humidity (%): 55±15
- Photoperiod (hrs dark / hrs light): 12/12 - Route of administration:
- other: Oral - gavage (single administration: Group 1, 2 and 3; repeated administration: group 5); intravenous (single administration: group 4)
- Vehicle:
- other: Oral (group 1, 2, 3 und 5): 0.8 % aqueous hydroxypropyl-ethyl-cellulose gel; Intravenous (group 4): 0.9 % NaCl solution
- Duration and frequency of treatment / exposure:
- single oral administration: Group 1, 2 and 3
repeated oral administration: group 5; once daily for 13 d
single intravenous administration: group 4 - Dose / conc.:
- 30 mg/kg bw/day
- Remarks:
- each dose contained 0.49 mg 14C-labelled test item/kg bw corresponding to a radioactive dose of 700 kBq/kg bw.
- Dose / conc.:
- 100 mg/kg bw/day
- Remarks:
- each dose contained 0.49 mg 14C-labelled test item/kg bw corresponding to a radioactive dose of 700 kBq/kg bw.
- No. of animals per sex per dose / concentration:
- Group 1 (low dose): 8 females
Group 2 (low dose): 4 males and 4 females
Group 3 (high dose): 4 males and 4 females
Group 4 (low dose): 8 females
Group 5 (repeated low dose): 4 females - Control animals:
- no
- Details on study design:
- Pilot study:
In order to determine the high dose level for the main study an orientating acute oral toxicity test and a preliminary excretion experiment to determine the relevance of excretion via expired air were carried out. Based on the results of these preliminary studies the following decisions were made for main study:
A high dose level of 100 mg/kg bw was used in the main study;
Excretion of test substance via expired air was significant and thus measured during main study. - Statistics:
- Pharmacokinetic evaluation of plasma data using program TopFit 2.11
- Preliminary studies:
- The following no-effects levels were determined in an orientating experiment:
NOEL rat, i.v. = 125 mg/kg bw; NOEL rat, p.o = 400 mg/kg bw.
The administered radioactivity was distributed as follows: Approximately 55 %/19 % (p.o./i.v.) in the faeces, 6 %/23 % in urine, 0.6 %/0.9 % in cage wash, and 12 % (p.o.) in expired air. The mean of the highest plasma concentration was 0.04 %/0.25 % (p.o./i.v.). The fraction of radioactivity excreted in expired air indicated that this route of elimination is relevant. - Type:
- absorption
- Results:
- 34% oral absorption
- Type:
- distribution
- Results:
- throughout the body, with the highest levels in the residual carcass, in the liver, the kidneys, and the adipose tissue
- Type:
- metabolism
- Results:
- mainly oxidation (hydroxylation), to a minor extent dehydrogenation and acetylation
- Type:
- excretion
- Results:
- excreted rapidly within 24 hours; main elimination pathway: via the faeces, followed by expired air and urine
- Details on absorption:
- Oral absorption: The systemic bioavailability of 14C labelled test substance was 34 % following oral administration, as derived from the comparison of the AUC0–∞ (see Table A6.2- 2).
- Details on distribution in tissues:
- Radioactivity was distributed throughout the body, with the highest levels in the residual carcass, in the liver, the kidneys, and the adipose tissue. Nevertheless, distribution was quite uniform across all examined organs with no tissue storage in brain, heart, ovaries and spinal cord. There was no significant difference in the distribution of radioactivity in the tissues after single or repeated administration of 30 mg test substance/kg bw.
Results of tissue distribution are summarised in the Table A6.2- 3. - Details on excretion:
- The vast majority of the administered radioactivity was excreted rapidly within 24 hours.
The main elimination pathway was via the faeces, followed by expired air and urine in all test groups. See Table A6.2- 1 for details.
After 168 hours approximately 60% of the radioactivity administered had been excreted via the faeces in the male and female animals, approximately 18% was excreted via expired air (approx. 15% in the males, 20% in the females), and approximately 9% was recovered in the urine. Less than 20% was found in organs and carcass.
There were no relevant differences in the mean radioactive recovery after 24 or 168 hours from urine and cage wash between the low, high, and repeated dose groups (see Table A6.2- 1). - Metabolites identified:
- yes
- Details on metabolites:
- In urine, the parent compounds N-C12 Gly, N’-C12 Gly, N’-C12 di Gly, C12 PDA and several metabolites were identified by mass spectrometry. Oxidation (hydroxylation) of the parent and some other metabolites like dehydrogenated and acetylated compounds, especially for C12 PDA, were identified. The most abundant compounds in urine were the oxidation products.
In plasma, only the unchanged parent compounds N-C12 Gly, N’-C12 Gly, N’-C12 di Gly, C12 PDA could be identified by mass spectrometry. For the radioactivity counting only N-C12 Gly, N’-C12 Gly were identified. The most abundant compounds in plasma were the parent substance N-C12 Gly and N’-C12 Gly.
In faeces, N-C12 Gly, N’-C12 Gly, N’-C12 di Gly, C12 PDA and several metabolites were identified by mass spectrometry. Oxidation (hydroxylation) of the parent and some other metabolites, like dehydrogenated and acetylated modifications, was demonstrated. The most abundant compounds in faeces were the oxidation products. - Conclusions:
- Interpretation of results: low bioaccumulation potential based on study results
The systemic bioavailability of 14C labelled registration substance was 34% following oral administration.
The substance was distributed throughout the body, with the highest levels in the residual carcass, in the liver, the kidneys, and the adipose tissue.
The plasma half-life was determined to be approx. 74 h.
The substance is mainly metabolised by oxidation (hydroxylation), and to a minor extent dehydrogenation and acetylation.
The vast majority of the administered radioactivity was excreted rapidly within 24 hours. The main elimination pathway was via the faeces, followed by expired air and urine. - Executive summary:
Absorption, distribution, metabolism and excretion of [14C]- registration substance (20% a.i.) were investigated in the rat according to the OECD test guideline 417. The test substance was administered orally by gavage at two single dose levels of 30 and 100 mg/kg bw, singly intravenous and orally at one repeated low dose level.
Upon oral administration, radioacitivity was predominantly eliminated via faeces (approx. 60 %) and via expired air (approx. 18 %). A lower proportion was excreted via urine (approx. 9 %) and less than 20 % of the administered dose was found in the carcass. No significant differences of absorption and elimination of test substance regarding high or low dose, repeated administration or sex could be indentified. The recovery of radioactivity was greatest in the residual carcass (12–19 %), followed by the liver (approx 4 %). In all other tissues the radioactive recovery was low (≤ 1.00 %) and quite uniformly distributed, with no tissue storage in brain, heart, ovaries and spinal cord. There was no relevant difference in the tissue distribution of radioactivity between animals treated orally or intravenously with a single or repeated dose of the test substance. The elimination half-life was approx. 74 hours both in the p.o. and i.v. group.
The systemic bioavailability, assessed by comparison of plasma radioactivity after oral and intravenous administration, was 34%.
In plasma, only parent substances but no transformation products could be identified. A first-pass effect following intestinal absorption is therefore unlikely. In urine and faeces, parent substances as well as transformation products were detected. Metabolites in both urine and faeces were characterised by oxidation (hydroxylation) of the parent and some other metabolites like dehydrogenated and acetylated compounds. The most abundant compounds in urine were the oxidation products.
- Endpoint:
- dermal absorption in vitro / ex vivo
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 428 (Skin Absorption: In Vitro Method)
- Version / remarks:
- 2004
- Deviations:
- no
- GLP compliance:
- yes
- Radiolabelling:
- yes
- Species:
- human
- Sex:
- female
- Type of coverage:
- open
- Vehicle:
- other: tap water
- Duration of exposure:
- 6 hours
Termination by washing skin sample surface with commercial soap concentrate followed by rinsing with a dilute soap solution and drying with tissue swabs. - Doses:
- Test preparation 1: 14C test substance (21.094 % a.i.) determined by radioactivity
Test preparation 2: 14C test substance (0.228 % a.i.) determined by radioactivity (diluted with tap water) - Details on in vitro test system (if applicable):
- SKIN PREPARATION
- Skin samples: Split-thickness human skin membrane samples
APPARATUS
Automated flow-through diffusion cell apparatus (Scott/Dick, University of Newcastle-upon-Tyne, UK), placed in a steel manifold heated via a circulating water bath to maintain the skin surface temperature. The cells were connected to multi-channel peristaltic pumps from their afferent ports with the receptor fluid effluent dropping via fine bore tubing into scintillation vials on a fraction collector.
PRINCIPLES OF ASSAY
- Volume applied: 10 µL/cm²; the surface area of exposed skin within the cells was 0.64 cm².
- Receptor fluid: Tissue culture medium containing bovine serum albumin (ca 5%, w/v), glucose (ca 1%, w/v), streptomycin (0.1 mg/mL) and penicillin G (100 units/mL). The receptor chamber volume was 0.25 mL, the peristaltic pumps were adjusted to maintain a flow-rate of ca 1.5 mL/h. - Signs and symptoms of toxicity:
- not examined
- Remarks:
- not applicable
- Dermal irritation:
- no effects
- Total recovery:
- Test preparation 1, 20 % (w/w): 101.69 % (SD = 3.04%)
Test preparation 2, 0.2 % (w/w): 97.10 % (SD = 2.99%) - Key result
- Dose:
- 20%
- Parameter:
- percentage
- Absorption:
- 1.1 %
- Remarks on result:
- other: 24 h
- Remarks:
- potentially absorbable dose (sum of the absorbed dose, exposed skin and stratum corneum tape strips 3–20)
- Key result
- Dose:
- 0.2%
- Parameter:
- percentage
- Absorption:
- 15.1 %
- Remarks on result:
- other: 24 h
- Remarks:
- potentially absorbable dose (sum of the absorbed dose, exposed skin and stratum corneum tape strips 3–20)
- Dose:
- 20%
- Parameter:
- percentage
- Absorption:
- 0.6 %
- Remarks on result:
- other: 24 h
- Remarks:
- Dermal delivery (exposed skin + absorbed dose)
- Dose:
- 0.2%
- Parameter:
- percentage
- Absorption:
- 5 %
- Remarks on result:
- other: Dermal delivery (exposed skin + absorbed dose)
- Conclusions:
- The systemically available dose of the registration substance (= dermal delivery: exposed skin + absorbed dose) was 0.6 ± 0.6% for the high exposure scenario (20% a.i.), and 5.0±2.5% for the low exposure scenario (0.2% a.i.), respectively.
The potentially absorbable dose of the registration substance was 1.1 ± 0.9% for the high exposure scenario (20% a.i.), and 15.1 ± 3.6% for the low exposure scenario (0.2% a.i.), respectively. - Executive summary:
The percutaneous absorption of [14C]-Amines, N-C10 -16 -alkyltrimethylenedi-, reaction products with chloracetic acid was tested according toOECD 428: Skin Absorption: In Vitro Method (2004).
Split-thickness human skin membranes were mounted into flow-through diffusion cells. Receptor fluid, consisting of bovine serum albumin (ca. 5%), glucose (ca 1%), streptomycin (0.1 mg/mL), and penicillin G (100 U/mL), was pumped underneath the skin at a flow rate of ca 1.5 mL/h. Receptor fluid was collected in hourly fractions and analysed by liquid scintillation counting.
Test preparation 1, 20 % (w/w): Mass balance 101.69 % (SD = 3.04%), thus considered to be complete.
Absorbed dose: 0.01 % (0.18 ng equivalent/cm²)
Dermal delivery: 0.62 % (13.17 ng equivalent /cm²)
Potentially absorbable dose(sum of absorbed dose, exposed skin and stratum corneum tape strips 6–20): 0.97 % (20.53 ng equivalent /cm²)
Test preparation 2, 0.2 % (w/w): Mass balance 97.10 % (SD = 2.99%), thus considered to be complete.
Absorbed dose: 0.11 % (0.02 ng equivalent /cm²)
Dermal delivery: 5.04 % (1.01 ng equivalent /cm²)
Potentially absorbable dose (sum of absorbed dose, exposed skin and stratum corneum tape strips 6–20): 11.42 % (2.28 ng equivalent /cm²)
However, according to EFSA Guidance on Dermal Absorption (2012) as well as the EU Guidance Document on Dermal Absorption (2004) only the first 2 tape strips should be discarded. On that basis the potentially absorbable dose for both low and high doses has been re-calculated.
The potentially absorbable dose (the sum of the absorbed dose, exposed skin and stratum corneum tape strips 3–20 may be used for risk assessment; this corresponds to 1.1 ±0.9% for the high exposure (20% a.i.), and 15.1±3.6% for the low exposure scenario (0.2 % a.i.), respectively.
For REACH-purposes the
"Dermal absorption represents the amount of topically applied test substance that is found in the epidermis (stratum corneum excluded) and in the dermis, and this quantity is therefore taken as systemically available. Dermal absorption is influenced by many factors, e.g. physico-chemical properties of the substance, its vehicle and concentration, and the exposure pattern (e.g. occlusion of the application site) as well as the skin site of the body (for review see ECETOC, 1993; Howes et al, 1996; Schaefer and Redelmaier, 1996). The term percutaneous penetration refers to in vitro experiments and represents the amount of topically applied test substance that is found in the receptor fluid – this quantity is taken as systemically available. " (Guidance on Information requirements and chemical safety assessment, R.7c).
Referenceopen allclose all
Toxic effects, clinical signs |
In the main experiment one male animal died prematurely and was found dead on test day 6. This death was not test item-related, but caused by a congested and blocked absorber for CO2determination. The faeces of all rats showed a normal consistency during the entire experimental period. No other effects were reported. |
Recovery of labelled compound |
Total recovery of administered radioactivity as determined in the excretion studies ranged from 97 to 103 % (rounded, seeTable A6.2-1). |
Pharmacokinetics |
After administration of 30 mg/kg bw (low dose) of [14C]-labeled test substancevia the oral and intravenous route the following toxicokinetic parameters were established: Plasma half-life: approx. 74 h both in the p.o. and i.v. group |
Table A6.2-1:Excretion: Mean recovery of radioactivity (%) after administration of [14C]-labelled test substance
|
Group 2: Single low dose |
Group 3: Single high dose |
Group 5: Repeated low dose |
||
|
Male |
Female |
Male |
Female |
Female |
Number of animals |
4 |
4 |
4 |
4 |
4 |
Urine (0–24 h) |
6.88 |
6.65 |
7.92 |
7.77 |
6.62 |
Urine (0–168 h) |
8.59 |
8.39 |
9.84 |
10.03 |
8.92 |
Faeces (0–24 h) |
51.06 |
51.72 |
49.03 |
44.01 |
42.35 |
Faeces (0–168 h) |
59.32 |
59.47 |
58.55 |
57.68 |
54.17 |
Expired air (0–24 h) |
10.13 |
12.74 |
9.85 |
13.00 |
7.84 |
Expired air (0–168 h) |
15.39 |
21.49 |
15.57 |
21.53 |
13.76 |
Cage wash (0–168 h) |
0.31 |
0.28 |
0.15 |
0.34 |
0.40 |
Carcass and organs |
n.e. |
13.33* |
n.e. |
n.e. |
19.22 |
Total |
|
102.96 |
|
|
96.47 |
Data expressed as mean % of total dose (dpm) administered ± standard deviation * Values derived from test group 1 with 8 female test animals administered orally a single low dose of test substance n.e.: not examined |
Table A6.2-2:Toxicokinetic parameters for [14C]-labelled test substance.
Dosage |
Route of administration |
Noncompartmental analysis |
|||||
Cmax# |
tmax# |
t1/2 |
AUC0-120 h |
AUC0-¥h |
AUC/dose## |
||
30 mg/kg bw |
p.o. |
47.5 |
6.00 |
76.62 |
2733.30 |
4126.83 |
6.87 |
|
i.v. |
606.5 |
- |
71.28 |
9304.88 |
12121.16 |
16.76 |
# Values obtained from the analytical results, all other values calculated by toxicokinetic analysis ## Dose in Bq/kg b.w. (mean values per group) i.v. intravenous administration p.o. oral administration |
Table A6.2-3:Distribution:Mean recovery of radioactivity (%) in organs at termination
|
Group 1: Single oral dose |
Group 4: Single intravenous dose |
Group 5: Repeated oral dose |
|
Female |
Female |
Female |
Number of animals |
8 |
8 |
4 |
Adipose tissue |
0.07 |
0.11 |
0.15 |
Brain |
0.02 |
0.07 |
0.02 |
Carcass |
12.13 |
19.06 |
17.72 |
Heart |
0.02 |
0.09 |
0.03 |
Kidneys |
0.17 |
0.75 |
0.22 |
Liver |
0.91 |
3.72 |
1.06 |
Ovaries |
0.01 |
0.05 |
0.02 |
Spinal cord |
0.00 |
0.01 |
0.00 |
Total |
13.33 |
23.86 |
19.22 |
Data expressed as mean % of total dose (dpm) administered ± standard deviation |
Figure A6.2-1:Proposed pathway of the metabolism of N-C12 Gly
see attached Image file
Test preparation 1, 20 % (w/w):99.76 % of the applied dose was removed by washing at 6 h post application. At 24 h post application, the total dislodgeable dose was 100.35 % of the applied dose. The stratum corneum retained 0.72 % of the applied dose, 0.37 % was removed with the first 5 tape strips.
Absorbed dose: 0.01 % (0.18 ng equivalent/cm²)
Dermal delivery: 0.62 % (13.17 ng equivalent /cm²)
Potentially absorbable dose: 0.97 % (20.53 ng equivalent /cm²)
Test preparation 2, 0.2 % (w/w): 73.66 % of the applied dose was removed by washing at 6 h post application. At 24 h post application, the total dislodgeable dose was 75.30 % of the applied dose. The stratum corneum retained 16.08 % of the applied dose, 9.71 % was removed with the first 5 tape strips.
Absorbed dose: 0.11 % (0.02 ng equivalent /cm²)
Dermal delivery: 5.04 % (1.01 ng equivalent /cm²)
Potentially absorbable dose: 11.42 % (2.28 ng equivalent /cm²)
Table A6.2-4:Details on human skin.
Donor no. |
Sex/age of donor |
Site of sampling |
Supplier |
Membrane full-thickness (µm) |
Membrane split-thickness (µm) |
0164 |
F/28Y |
Breast |
St. Johns Hospital |
1010–1150 |
380–390 |
0161 |
F/36Y |
Abdomen |
BUPA |
1020–1080 |
390–400 |
0162 |
F/35Y |
Abdomen |
BUPA |
700–1190 |
390–400 |
0179 |
F/84Y |
Breast |
Nottingham |
1130 |
400 |
0169 |
F/82Y |
Breast |
Nottingham |
1000 |
400 |
0180 |
F/74Y |
Breast |
Nottingham |
940–1000 |
400 |
0166 |
F/33Y |
Abdomen |
Transkin |
1240 |
400 |
Table A6.2-5:Summary of the results (mean values).
Test preparation |
1 |
2 |
||
Target concentration of active substance |
20 % (w/w) |
0.2 % (w/w) |
||
Active substance concentration in test preparation by radioactivity |
21.016 % (w/w) |
0.199 % (w/w) |
||
Application rate of Test preparation |
10.06 mg/cm² |
10 µl/cm² |
||
Application rate of test item |
2114 µg equivalent/cm² |
19.94 µg equivalent/cm² |
||
Distribution |
% applied dose |
ng equivalent /cm² |
% applied dose |
ng equivalent /cm² |
Dislodgeable dose 6 h |
99.76 |
2108.47 |
73.66 |
14.69 |
Total dislodgeable dose |
100.35 |
2120.83 |
75.30 |
15.02 |
Unabsorbed dose |
101.07 |
2136.17 |
92.06 |
18.36 |
Absorbed dose |
0.01 |
0.18 |
0.11 |
0.02 |
Dermal delivery |
0.62 |
13.17 |
5.04 |
1.01 |
Potentially absorbable dose |
0.97 |
20.53 |
11.42 |
2.28 |
Mass balance |
101.69 |
2149.34 |
97.10 |
19.36 |
According to EFSA Guidance on Dermal Absorption (2012) as well as the EU Guidance Document
on Dermal Absorption (2004) only the first 2 tape strips should be discarded. On that basis dermal absorption for both low and high doses have been re-calculated.
Recalculation disregarding 2 rather than 5 tape strips:
Prep 1 (20% a.i.) |
||||||||||||
|
Cell 1 |
Cell 2 |
Cell 3 |
Cell 4 |
Cell 8 |
Cell 9 |
Cell 10 |
Cell 12 |
Cell 13 |
Cell 14 |
Mean |
STDEV |
1 |
0.008 |
0.019 |
0.08 |
0.068 |
0.18 |
|
0.282 |
0.12 |
0.023 |
0.144 |
0.103 |
0.090 |
2 |
0.003 |
0.011 |
0.141 |
0.099 |
0.093 |
|
0.295 |
0.063 |
0.01 |
0.201 |
0.102 |
0.098 |
Stratum total |
0.04 |
0.1 |
0.99 |
0.69 |
0.95 |
|
1.58 |
0.62 |
0.16 |
1.33 |
0.718 |
0.549 |
minus 1+2 |
0.029 |
0.07 |
0.769 |
0.523 |
0.677 |
|
1.003 |
0.437 |
0.127 |
0.985 |
0.513 |
0.378 |
Dermal delivery |
0.02 |
0.09 |
0.77 |
0.27 |
1.35 |
|
1.73 |
0.82 |
0.15 |
0.41 |
0.623 |
0.597 |
Absorbable Dose |
0.049 |
0.16 |
1.539 |
0.793 |
2.027 |
|
2.733 |
1.257 |
0.277 |
1.395 |
1.137 |
0.907 |
Prep 2 (0.2% a.i.) |
||||||||||||
|
Cell 16 |
Cell 17 |
Cell 18 |
Cell 19 |
Cell 24 |
Cell 25 |
Cell 26 |
Cell 28 |
Cell 29 |
Cell 30 |
Mean |
STDEV |
1 |
3.11 |
2.24 |
2.84 |
4.42 |
3.36 |
3.89 |
4.82 |
3.78 |
4.87 |
6.06 |
3.939 |
1.131 |
2 |
1.66 |
1.8 |
1.71 |
2.33 |
1.73 |
2.53 |
2.19 |
2.26 |
2.5 |
2.26 |
2.097 |
0.338 |
Stratum total |
12.02 |
13.59 |
14.46 |
19.48 |
15.39 |
15.49 |
20.79 |
16.73 |
14.73 |
18.17 |
16.085 |
2.718 |
minus 1+2 |
7.25 |
9.55 |
9.91 |
12.73 |
10.3 |
9.07 |
13.78 |
10.69 |
7.36 |
9.85 |
10.049 |
2.052 |
Dermal delivery |
2.56 |
2.52 |
3.84 |
3.15 |
8.21 |
9.37 |
6.12 |
7.47 |
3.15 |
4.02 |
5.041 |
2.538 |
Absorbable Dose |
9.81 |
12.07 |
13.75 |
15.88 |
18.51 |
18.44 |
19.9 |
18.16 |
10.51 |
13.87 |
15.090 |
3.611 |
Description of key information
Based on physicochemical properties and identified uses, the potential
for inhalation of components of the registration substance either as
vapour or dust appears marginal.
The oral bioavailability was determined to be 34% (OECD guideline 417,
GLP; rat).
The systemically available dose after dermal administration was
determined to be 0.6±0.6% for the high exposure scenario (20% a.i.), and
5.0±2.5% for the low exposure scenario (0.2% a.i.), respectively (OECD
guideline 428, GLP; human skin).
Key value for chemical safety assessment
- Bioaccumulation potential:
- no bioaccumulation potential
- Absorption rate - oral (%):
- 50
- Absorption rate - dermal (%):
- 5
- Absorption rate - inhalation (%):
- 100
Additional information
Inhalative absorption
The substance as a 20% aqueous solution of Amines, N-C10 -C16 -alkyltrimethylenedi-, reaction products with chloroacetic acid (“product by process”), is not volatile (vapour pressure < 1.9 × 10–4 Pa). The substance is neither a powder nor is it to be included in powdery preparations. Furthermore, the substance is not intended to be applied in a manner leading to generation of aerosols, particles or droplets in the inhalable size range (MMAD < 50 µm). Therefore, the potential for inhalation of components of the registration substance either as vapour or dust appears marginal.
However, for chemical safety assessment by default 100% absorption will be assumed in accordance with REACH TGD as no experimental data concerning absorption after inhalative exposure are available.
Oral absorption
Absorption of [14C]- Amines, N-C10 -C16 -alkyltrimethylenedi-, reaction products with chloroacetic acid (20% a.i.) was investigated in the rat (OECD guideline 417). The test substance was administered orally by gavage at two single dose levels of 30 and 100 mg/kg bw, singly intravenous and orally at one repeated low dose level.
The systemic bioavailability, assessed by comparison of plasma radioactivity after oral and intravenous administration, was 34%.
This finding is also supported by the physicochemical properties: The registration substance is freely miscible with water (>200 g/L, according to the product being a 20% aqueous solution). In view of the amphoteric properties, the log Dow has been estimated by QSAR at 2.33. Consequently, the registration substance may be assumed to be readily dissolved in gastrointestinal fluids and subsequently available for passage through the epithelial barrier of the GI tract by passive diffusion.
Also the toxicological signs observed in the 90-d studies in rats at relatively low doses (approx. 3.0–20 mg a.i./kg bw/d) suggest high oral absorption.
The Guidance on Information requirements and Chemical Safety Assessment, R.7c (Nov. 2012) states: “In practice, an adjustment in oral toxicity factor (to account for absorbed dose in the dermal exposure pathway) is recommended when the following conditions are met: (1) the toxicity value derived from the critical study is based on an administered dose (e.g., delivery in diet or by gavage) in its study design; (2) a scientifically defensible database demonstrates that the GI absorption of the chemical in question, from a medium (e.g., water, feed) similar to the one employed in the critical study, is significantly less than 100% (e.g., <50%). A cut-off of 50% GI absorption is recommended to reflect the intrinsic variability in the analysis of absorption studies. Thus, this cut-off level obviates the need to make comparatively small adjustments in the toxicity value that would otherwise impart on the process a level of accuracy that is not supported by the scientific literature.”
Thus an oral absorption of 50% will be used for chemical safety assessment.
Dermal absorption
The percutaneous absorption of [14C]-Amines, N-C10 -C16 -alkyltrimethylenedi-, reaction products with chloroacetic acid was tested according to OECD guideline 428 (A6.2/03) in an in vitro study at two different concentrations. It could be shown for a 20% test preparation (aqueous solution) that 99.76 % of the applied dose was removed from the skin by washing at 6 h post application. With a mass balance of 101.7% it was concluded that the absorbed dose, dermal delivery and potentially absorbable dose were 0.01 % (0.18 ng equivalent/cm²), 0.62 % (13.17 ng equivalent /cm²) and 0.97 % (20.53 ng equivalent /cm²), respectively. The second test preparation, 0.2% [14C]-Amines, N-C10 -C16 -alkyltrimethylenedi-, reaction products with chloroacetic acid
as aqueous solution, resulted in 73.66 % removable dose by washing at 6 h post application and 0.11 % (0.02 ng equivalent /cm²), 5.04 % (1.01 ng equivalent /cm²) and 11.42 % (2.28 ng equivalent /cm²) of the applied dose, absorbed dose, dermal delivery and potentially absorbable dose, respectively (97.1 % mass balance).
According to the Guidance on Information requirements and chemical safety assessment, R.7c: "Dermal absorption represents the amount of topically applied test substance that is found in the epidermis (stratum corneum excluded) and in the dermis, and this quantity is therefore taken as systemically available. Dermal absorption is influenced by many factors, e.g. physico-chemical properties of the substance, its vehicle and concentration, and the exposure pattern (e.g. occlusion of the application site) as well as the skin site of the body […]. The term percutaneous penetration refers to in vitro experiments and represents the amount of topically applied test substance that is found in the receptor fluid – this quantity is taken as systemically available."
Thus, the systemically available dose of the registration substance (= dermal delivery: exposed skin + absorbed dose) was 0.6 ± 0.6% for the high exposure scenario (20% a.i.), and 5.0 ± 2.5% for the low exposure scenario (0.2% a.i.), respectively. The high exposure scenario (20% a.i.) is relevant for chemical safety assessment of worker uses. A dermal absorption of 1% will be applied for those assessments.
The low exposure scenario (0.2% a.i.) is relevant for the chemical safety assessment of consumer uses. For those assessments, a dermal absorption of 5% will be applied.
Distribution, metabolism and excretion
Distribution, metabolism and excretion of [14C]-Amines, N-C10 -C16 -alkyltrimethylenedi-, reaction products with chloroacetic acid (20% a.i.) were investigated in the rat according to the OECD test guideline 417. The test substance was administered orally by gavage at two single dose levels of 30 and 100 mg/kg bw, singly intravenous and orally at one repeated low dose level.
Upon oral administration, radioacitivity was predominantly eliminated via faeces (approx. 60 %) and via expired air (approx. 18 %). A lower proportion was excreted via urine (approx. 9 %) and less than 20 % of the administered dose was found in the carcass. No significant differences of absorption and elimination of test substance regarding high or low dose, repeated administration or sex could be identified. The recovery of radioactivity was greatest in the residual carcass (12–19 %), followed by the liver (approx 4 %). In all other tissues the radioactive recovery was low (≤ 1.00 %) and quite uniformly distributed, with no tissue storage in brain, heart, ovaries and spinal cord. There was no relevant difference in the tissue distribution of radioactivity between animals treated orally or intravenously with a single or repeated dose of the test substance. The elimination half-life was approx. 74 hours both in the p.o. and i.v. group.
In plasma, only parent substances but no transformation products could be identified. A first-pass effect following intestinal absorption is therefore unlikely. In urine and faeces, parent substances as well as transformation products were detected. Metabolites in both urine and faeces were characterised by oxidation (hydroxylation) of the parent and some other metabolites like dehydrogenated and acetylated compounds. The most abundant compounds in urine were the oxidation products.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.